Drugs and Devices

FDA expands Zytiga’s use for late-stage breast cancer

On Dec. 10, the U.S. Food and Drug Administration expanded the approved use of Zytiga (abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer before receiving chemotherapy. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares